Loading company…
TECregen develops thymus-regenerating therapies intended to restore immune function and balance.
TECregen develops thymopoietic therapies designed to regenerate the thymus and restore immune function. Its work includes biologics intended for immune decline, cancer, and inflammatory diseases. Founded in 2024, the company is based in Basel, Switzerland. In January 2026, it raised CHF 10 million in seed funding led by Boehringer Ingelheim Venture, with participation from LifeSpan Vision Ventures, CARMA FUND Management, Eos BioInnovation, High-Tech Gruenderfonds, JFG Life Sciences Foundation, and Zurich Cantonal Bank.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in